What is the role of tirilazad mesylate in the treatment of cauda equina and conus medullaris syndrome?

Updated: Jun 14, 2018
  • Author: Segun Toyin Dawodu, JD, MD, MS, MBA, LLM, FAAPMR, FAANEM; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
  • Print
Answer

Tirilazad mesylate (a nonglucocorticoid 21-aminosteroid) has been proven to be of benefit in animals and is currently under investigation. It inhibits lipid peroxidation and hydrolysis in the same manner as glucocorticoids.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!